NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Mayo, MJ; Wigg, AJ; Roberts, SK; Arnold, H; Hassanein, TI; Leggett, BA; Bate, JP; Weltman, M; Carey, EJ; Muir, AJ; McCaughan, G; Bollipo, SJ; Gordon, SC; Angus, PW; Riordan, S; Shiffman, ML; Young, E; Ling, L; Luo, J; Elliott, M; Rossi, S; DePaoli, AM; Thompson, AJ

Published Date

  • October 1, 2015

Published In

Volume / Issue

  • 62 /

Start / End Page

  • 263A - 264A

Published By


  • 2

Electronic International Standard Serial Number (EISSN)

  • 1527-3350

International Standard Serial Number (ISSN)

  • 0270-9139

Conference Name

  • 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)

Conference Location

  • San Francisco, CA

Conference Start Date

  • November 13, 2015

Conference End Date

  • November 17, 2015